» Articles » PMID: 39851963

Towards Personalized Radiotherapy in Pelvic Cancer: Patient-Related Risk Factors for Late Radiation Toxicity

Overview
Journal Curr Oncol
Publisher MDPI
Date 2025 Jan 24
PMID 39851963
Authors
Affiliations
Soon will be listed here.
Abstract

Normal tissue reactions vary significantly among patients receiving the same radiation treatment regimen, reflecting the multifactorial etiology of late radiation toxicity. Predicting late radiation toxicity is crucial, as it aids in the initial decision-making process regarding the treatment modalities. For patients undergoing radiotherapy, anticipating late toxicity allows for planning adjustments to optimize individualized care. Various dosimetric parameters have been shown to influence the incidence of late toxicity, and the literature available on this topic is extensive. This narrative review examines patient-related determinants of late toxicity following external beam radiotherapy for pelvic tumors, with a focus on prostate and cervical cancer patients. In Part I, we address various methods for quantifying radiation toxicity, providing context for interpreting toxicity data. Part II examines the current insights into the clinical risk factors for late toxicity. While certain factors-such as previous abdominal surgery, smoking behavior, and severe acute toxicity-have consistently been reported, most of the others show inconsistent associations. In Part III, we explore the influence of genetic factors and discuss promising predictive assays. Single-nucleotide polymorphisms (SNPs) likely elevate the risk in specific combinations. Advances in artificial intelligence now allow for the identification of SNP patterns from large datasets, supporting the development of polygenic risk scores. These innovations hold promise for improving personalized treatment strategies and reducing the burden of late toxicity in cancer survivors.

References
1.
Chinnachamy A, Chopra S, Krishnatry R, Kannan S, Thomas B, Mahantshetty U . Evaluation of interobserver and interscale agreement in assessing late bowel toxicity after pelvic radiation in patients with carcinoma of the cervix. Jpn J Clin Oncol. 2013; 43(5):508-14. DOI: 10.1093/jjco/hyt028. View

2.
Kerns S, Stock R, Stone N, Buckstein M, Shao Y, Campbell C . A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of erectile dysfunction following radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 85(1):e21-8. PMC: 3616619. DOI: 10.1016/j.ijrobp.2012.08.003. View

3.
Nuijens A, Oei A, Bouhuijs A, Franken N, Rasch C, Stalpers L . A Comparison between Patient- and Physician-Reported Late Radiation Toxicity in Long-Term Prostate Cancer Survivors. Cancers (Basel). 2022; 14(7). PMC: 8996858. DOI: 10.3390/cancers14071670. View

4.
Browman G, Wong G, HODSON I, Sathya J, Russell R, McAlpine L . Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med. 1993; 328(3):159-63. DOI: 10.1056/NEJM199301213280302. View

5.
Rubin P, Constine L, Fajardo L, Phillips T, Wasserman T . RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues (LENT) scoring system. Int J Radiat Oncol Biol Phys. 1995; 31(5):1041-2. DOI: 10.1016/0360-3016(95)00057-6. View